Skip to contentI
InspireMD, Inc.
I
NSPRInspireMD, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.95M$1.95Mderived+10.7% vs Q4 2023 Net Income-$9.17M-$9.17MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
InspireMD, Inc. · CIK 1433607 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$469,000−7.1% Operating Incomederived-$9,367,000N/M Operating Cash Flowderived-$6,750,000N/M Free Cash Flowderived-$7,061,000N/M Margins · derivedGross margin24.1%−4.6 pt vs Q4 2023
Operating margin-480.6%−150.8 pt vs Q4 2023
Net margin-470.7%−163.8 pt vs Q4 2023
ended Dec 31, 2024 · filed Mar 12, 2025 · 71 d after period end